Peringatan Keamanan

Hypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat)

Dipyridamole

DB00975

small molecule approved

Deskripsi

A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)

Struktur Molekul 2D

Berat 504.6256
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 40 minutes
Volume Distribusi * 1 to 2.5 L/kg
Klirens (Clearance) * 2.3-3.5 mL/min/kg

Absorpsi

70%

Metabolisme

hepatic

Rute Eliminasi

Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.

Interaksi Makanan

3 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
  • 2. Avoid xanthines. Xanthines, found in coffee and tea, can reduce the effectiveness of this medication.
  • 3. Take with or without food. Taking dipyridamole extrended release capusels with a high-fat meal minimally reduces it's AUC and Cmax.

Interaksi Obat

1092 Data
Apixaban Apixaban may increase the anticoagulant activities of Dipyridamole.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Dipyridamole.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dipyridamole.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Dipyridamole is combined with Deferasirox.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Dipyridamole.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dipyridamole.
Rivaroxaban Dipyridamole may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Dipyridamole is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Dipyridamole.
Urokinase Urokinase may increase the anticoagulant activities of Dipyridamole.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Dipyridamole.
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Dipyridamole is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Dipyridamole is combined with Levodopa.
Risperidone Dipyridamole may increase the hypotensive activities of Risperidone.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Dipyridamole is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Dipyridamole is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Dipyridamole.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.
Obinutuzumab The risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.
Tipranavir Tipranavir may increase the antiplatelet activities of Dipyridamole.
Vitamin E Vitamin E may increase the antiplatelet activities of Dipyridamole.
Olmesartan Olmesartan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Troglitazone Troglitazone may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Reserpine Reserpine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Cimetidine Cimetidine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Bosentan Bosentan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Glyburide Glyburide may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Ketoconazole Ketoconazole may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Fusidic acid Fusidic acid may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Simeprevir Simeprevir may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Lenvatinib Lenvatinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Letermovir The excretion of Letermovir can be decreased when combined with Dipyridamole.
Valinomycin Valinomycin may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Cyclosporine Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Pralsetinib Pralsetinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.
Esmolol Dipyridamole may increase the bradycardic activities of Esmolol.
Betaxolol Dipyridamole may increase the bradycardic activities of Betaxolol.
Metoprolol Dipyridamole may increase the bradycardic activities of Metoprolol.
Atenolol Dipyridamole may increase the bradycardic activities of Atenolol.
Timolol Dipyridamole may increase the bradycardic activities of Timolol.
Sotalol Dipyridamole may increase the bradycardic activities of Sotalol.
Propranolol Dipyridamole may increase the bradycardic activities of Propranolol.
Labetalol Dipyridamole may increase the bradycardic activities of Labetalol.
Bisoprolol Dipyridamole may increase the bradycardic activities of Bisoprolol.
Alprenolol Dipyridamole may increase the bradycardic activities of Alprenolol.
Pindolol Dipyridamole may increase the bradycardic activities of Pindolol.
Carvedilol Dipyridamole may increase the bradycardic activities of Carvedilol.
Propafenone Dipyridamole may increase the bradycardic activities of Propafenone.
Acebutolol Dipyridamole may increase the bradycardic activities of Acebutolol.
Nadolol Dipyridamole may increase the bradycardic activities of Nadolol.
Bevantolol Dipyridamole may increase the bradycardic activities of Bevantolol.
Practolol Dipyridamole may increase the bradycardic activities of Practolol.
Penbutolol Dipyridamole may increase the bradycardic activities of Penbutolol.
Oxprenolol Dipyridamole may increase the bradycardic activities of Oxprenolol.
Dexpropranolol Dipyridamole may increase the bradycardic activities of Dexpropranolol.
Celiprolol Dipyridamole may increase the bradycardic activities of Celiprolol.
Nebivolol Dipyridamole may increase the bradycardic activities of Nebivolol.
Bufuralol Dipyridamole may increase the bradycardic activities of Bufuralol.
Bopindolol Dipyridamole may increase the bradycardic activities of Bopindolol.
Bupranolol Dipyridamole may increase the bradycardic activities of Bupranolol.
Indenolol Dipyridamole may increase the bradycardic activities of Indenolol.
Arotinolol Dipyridamole may increase the bradycardic activities of Arotinolol.
Levobetaxolol Dipyridamole may increase the bradycardic activities of Levobetaxolol.
Talinolol Dipyridamole may increase the bradycardic activities of Talinolol.
Anisodamine Dipyridamole may increase the bradycardic activities of Anisodamine.
Bucindolol Dipyridamole may increase the bradycardic activities of Bucindolol.
Esatenolol Dipyridamole may increase the bradycardic activities of Esatenolol.
Cloranolol Dipyridamole may increase the bradycardic activities of Cloranolol.
Mepindolol Dipyridamole may increase the bradycardic activities of Mepindolol.
Epanolol Dipyridamole may increase the bradycardic activities of Epanolol.
Tertatolol Dipyridamole may increase the bradycardic activities of Tertatolol.
Landiolol Dipyridamole may increase the bradycardic activities of Landiolol.
Alprostadil The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.
Amyl Nitrite The risk or severity of hypotension can be increased when Dipyridamole is combined with Amyl Nitrite.
Dapoxetine The risk or severity of orthostatic hypotension can be increased when Dapoxetine is combined with Dipyridamole.
Riociguat Dipyridamole may increase the hypotensive activities of Riociguat.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.
Mefloquine The therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.
Tacrine The therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole.
Sulpiride The therapeutic efficacy of Sulpiride can be decreased when used in combination with Dipyridamole.
Profenamine The therapeutic efficacy of Profenamine can be decreased when used in combination with Dipyridamole.
Chlorpromazine The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Dipyridamole.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with Dipyridamole.
Triflupromazine The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Dipyridamole.
Cisplatin The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole.
Cinchocaine The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Dipyridamole.
Pyridostigmine The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole.
Nizatidine The therapeutic efficacy of Nizatidine can be decreased when used in combination with Dipyridamole.
Galantamine The therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.

Target Protein

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A PDE10A
cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A
3',5'-cyclic-AMP phosphodiesterase 4A PDE4A
Adenosine deaminase ADA
Calcipressin-1 RCAN1
Alpha-1-acid glycoprotein 1 ORM1

Referensi & Sumber

Synthesis reference: Minutza Leibovici, Itamar Kanari, Michael Fox, "Dipyridamole extended-release formulations and process for preparing same." U.S. Patent US20070184110, issued August 09, 2007.
Artikel (PubMed)
  • PMID: 8981292
    Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13.

Contoh Produk & Brand

Produk: 126 • International brands: 5
Produk
  • Aggrenox
    Capsule • - • Oral • US • Approved
  • Aggrenox
    Capsule • - • Oral • US • Approved
  • Aggrenox
    Capsule, extended release • - • Oral • US • Approved
  • Aggrenox
    Capsule, extended release • - • Oral • US • Approved
  • Aggrenox
    Capsule, extended release • - • Oral • Canada • Approved
  • Apo-dipyridamole
    Tablet • 50 mg • Oral • Canada • Generic • Approved
  • Apo-dipyridamole
    Tablet • 25 mg • Oral • Canada • Generic • Approved
  • Apo-dipyridamole
    Tablet • 75 mg • Oral • Canada • Generic • Approved
Menampilkan 8 dari 126 produk.
International Brands
  • Agilease — lsei
  • Cardoxin — Rafa
  • Cleridium 150 — Millot
  • Curantyl — Arzneimittelwerk
  • Persantin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul